clinicalomicsprowebdirectory
News & Features
Topics
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Magazine
Multimedia
Webinars
eBooks
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Search
Advertise
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Lead Generation Campaigns
Email Nurture Campaigns
Custom Content Solutions
About Us
Contact Us
Mary Ann Liebert Publishers
Create a Free Account
Log In
Clinical OMICs – Molecular Diagnostics in Precision Medicine
News & Features
Molecular Dx
Nanomix Gets $570K from BARDA to Develop Rapid, POC COVID-19 Tests
Patient Care
A4 Study: Elevated Amyloid an early Sign of Alzheimer’s Disease
Precision Medicine
BillionToOne Goes Beyond qPCR with Sanger-Based COVID-19 Test
Immunotherapies
Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion
Patient Care
Coronavirus Replication Stopped in 48 Hours in Lab-Grown Cells by Anti-Parasitic…
Topics
All
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Molecular Dx
Nanomix Gets $570K from BARDA to Develop Rapid, POC COVID-19 Tests
Patient Care
A4 Study: Elevated Amyloid an early Sign of Alzheimer’s Disease
Precision Medicine
BillionToOne Goes Beyond qPCR with Sanger-Based COVID-19 Test
Immunotherapies
Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion
Magazine
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 2
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 1
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 6
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 5
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 4
Multimedia
All
Webinars
eBooks
eBooks
Clinical Research in a Real-Time Sequencing Age
Precision Medicine
From Bench to Clinic—The Potential of New Sequencing Tools
Precision Medicine
Mainstreaming Precision Oncology
eBooks
Better Understanding of Post-Translation Modifications Driving Innovation
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Home
Oncology
Immunotherapies
Immunotherapies
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Immunotherapies
Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion
April 7, 2020
Immunotherapies
A Triple-Pronged Approach to CAR T Therapy
April 6, 2020
Immunotherapies
Immunotherapy Linked to Thyroid Dysfunction
April 1, 2020
Immunotherapies
Removing EGR4 “Brake” on Immune Activation May Be Viable I/O Therapeutic...
March 26, 2020
Immunotherapies
The Accelerating Race for Immunotherapy Biomarkers
March 24, 2020
Immunotherapies
Immunotherapy Success Determined by Gut Microbiome
March 9, 2020
Immunotherapies
Molecular Mechanisms of Osteosarcoma Provide Clues for Improved Immunotherapy Strategies
February 24, 2020
Immunotherapies
Researchers Discover Molecular Pathway Involved in Immunotherapy Response
February 21, 2020
Immunotherapies
Map of Human Thymus Gland May Suggest New Immune Therapies
February 20, 2020
Immunotherapies
Engineered Probiotic Can Deliver Immune Checkpoint Inhibiting Nanobodies Directly to Tumors
February 14, 2020
Load more
Scroll Up
We use cookies to give you a better experience on clinicalomics.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![ArcherDX said its Archer Immunoverse and VariantPlex NGS assays will be used by Ambry toward offering its biopharma customers large-scale immune repertoire analysis and chimeric antigen T-cell receptor (CAR-T) manufacturing characterization and pharmacodynamics. [royaltystockphoto/Getty Images]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1550-324x160.jpeg "Removing EGR4 “Brake” on Immune Activation May Be Viable I/O Therapeutic Approach")
